ERBB2 and neoplasm: Concerning clinically relevant subgroups, we observed that NOTCH1 mRNA overexpression was associated with a significantly less favourable outcome in patients with HR-positive/HER2-negative tumours getting adjuvant chemotherapy (adjusted hazard ratio 3.6, 95% CI 1.16–11.17, p = 0.027).